How Angel Investors Really Evaluate Femtech Founders | Blush & Bloom Podcast | Ep. 30

Raising early-stage capital is hard for any founder, and women building in femtech often carry an extra weight: the sense that their category is a niche rather than a market. But what do angel investors actually look at when they decide who to back, and does the femtech label help or hurt when you walk into the room?

In this episode of Blush & Bloom, host Gigi Kenneth talks with Trine Hoffensetz Winther, executive director of DanBAN, Denmark's biggest network for business angels. With roughly 250 to 300 investors backing startups and scale-ups across sectors including health tech and life science, Trine has seen the ecosystem from every seat: founder, consultant, mentor, board member, and investor.

Together they unpack what really moves an early-stage investment decision, why the founding team beats the perfect plan, and how women's health innovation is finally shifting from an overlooked market to one of the most exciting spaces to build in.

In This Episode, We Cover:

• Why the founding team's resilience and grit matter more than a flawless idea
• What angel investors look for beyond the pitch deck
• Whether founders should inflate their numbers or lead with honesty
• The femtech label: helpful shorthand or a limiting box?
• How to pitch a femtech company the same way you would any other startup
• Why diverse investors lead to more diverse companies getting funded
• How investors are actually using AI, and where they still won't trust it

Why does the founding team matter more than the idea?

Because execution beats a perfect plan. Trine has assessed startups across many industries, and she keeps coming back to the people. A brilliant idea no one hears about, or one no one executes on, will not matter. The team's mindset, resilience, and ability to stand the course is what she looks at first, especially at the early stage when there are few metrics to judge.

"The founding team is Alpha Omega. You need to find someone that, one, they believe in the idea themselves."

Every industry has its own challenges, she notes, but the founder mindset is universal. Founders come in all shapes and sizes, and the ones who make it have the grit to keep going through what she calls a genuinely hard journey.

What do investors look for beyond the pitch deck?

Honesty and self-awareness. The standard signals still matter, the product, the innovation, the scalability, the business model, the go-to-market. But at the early stage, Trine wants to leave a meeting feeling there is realism behind the ambition, not just big claims with nothing to back them up.

"I would always rather have authenticity rather than just ambitious goals that are unobtainable."

She treats the budget and forecast less as a promise and more as an indicator of how well a founder understands their own business, including the blind spots and the costs, legal, regulatory, technical, that surprise so many first-time founders.

Should founders inflate their numbers?

Trine's view is that it depends on the journey the founder actually wants. Investors see plenty of hockey-stick projections, the classic curve where a startup explodes into a unicorn. But not every business needs that shape. Some founders are better suited to building a profitable, sustainable company, sometimes called a zebra, that creates jobs and lasts.

If the hockey stick is genuinely the ambition, then you have to show the metrics and prove it is possible. Everyone knows a forecast is a set of guesstimates, no one can predict the future. What matters is whether you can answer the tough questions when investors, or customers, start digging in, and whether you can explain why each number is there.

Is femtech a helpful label or a limiting one?

Both, and the answer changes depending on where the market is. Trine still finds it baffling that women's health gets treated as a niche. As she puts it, how can it be a niche when it is half the population? Historically it has been overlooked and underfunded, and a clear label can help nudge attention and money toward a whole vertical that investors might otherwise miss.

The risk is that the label can box a startup into a category some investors dismiss as hype. In an ideal world, she says, femtech would simply be health tech solving problems for 50 percent of the population, with an enormous market potential. But in the early days of correcting an underfunded space, naming it something recognizable is often what pulls the funding in.

How should femtech founders actually pitch?

Trine says she has been genuinely impressed by how well femtech founders pitch, and her core advice is simple: pitch as if you were any other founder. The femtech framing can justify why the category deserves to exist, but it should not be the focal point of the pitch itself.

"Focus on the key metrics, what makes your company special."

Targeting half the population is not a strategy, she points out, any more than saying you want to sell to everyone over 18. Investors will push back that it is too broad. The stronger move is to be specific: what exact problem are you solving, why is it relevant, and why will people pay for it?

Why do diverse investors matter for women's health?

Because people fund what they understand. Angel investors play an outsized role in the earliest, riskiest phases, often before venture capital steps in. But bias is real, and Trine is candid about it: a company pitching a menopause or menstruation product is simply easier to pitch to a woman who can relate to the need. That is not about bad intentions from male investors, it is about lived experience.

Her answer is structural. Networks and ecosystem players have a responsibility to surface a wide, diverse range of startups, because investors who want to back more women founders cannot do it if they never see the cases. And, she argues, the field needs to recruit more women investors so the balance shifts across boardrooms, investor networks, and the founder community alike.

How are investors using AI?

Carefully. Trine loves AI and uses it heavily, but she would still be nervous letting it make investment decisions, there are too many nuances in reading a pitch deck and a founder. Where it earns its keep is fact-checking, for example testing a "we have no competitors" claim, and speeding up due diligence and market analysis where there is a mountain of data points.

She also flags a founder-side risk. When a company brands itself as an AI business, she wants to look under the hood and confirm it is more than a nice package around ChatGPT, and that the founders have brought in experts on liability, GDPR, and the regulatory requirements. On the upside, AI now lets founders build a functional MVP and fundraise on it without deep coding skills, something that would have required raising money first a decade ago.

FAQ

What is DanBAN? DanBAN, the Danish Business Angels network, is Denmark's biggest network for business angels, with roughly 250 to 300 investors backing early-stage startups and scale-ups across sectors including health tech and life science. Its focus is connecting the right founders with the right investors.

What do angel investors look for in early-stage founders? At the early stage, when there are few metrics to assess, investors weigh the founding team most heavily: their belief in the idea, their resilience, their ability to execute, and their honesty about the risks and costs of their own business.

Is femtech a niche market? Trine argues it should not be seen as one, since women make up half the population. It has historically been overlooked and underfunded, but interest is growing as more people recognize the scale of the financial opportunity, not just the mission.

How should a femtech founder pitch to investors? Pitch it like any other startup. Lead with the specific problem, the solution, the business model, and why customers will pay, rather than making "we serve half the population" the centerpiece of the pitch.

Why does investor diversity matter in women's health? Investors tend to fund problems they personally understand. More women investors, and networks that actively surface diverse founders, help ensure strong women's health companies get seen and funded rather than flying under the radar.

💬 Final Thoughts

The through-line of this conversation is that femtech does not need special pleading, it needs to be understood as what it is: health tech with a market that spans half of humanity. Trine's advice to women founders pitching for the first time is to forget, for a moment, that they are a female founder pitching a femtech case, and instead own the room as a founder who knows their business cold. The bias is real and the data shows it, but getting too caught up in it can convince you that you have already lost before you have started. With more women stepping up as investors and founders, and areas like menopause and menstruation finally being treated as the normal, fundable problems they are, this is a genuinely exciting moment to be building in women's health.

👥 Connect with the Guest

Trine Hoffensetz Winther: https://www.linkedin.com/in/trinehoffensetz/

Gigi Kenneth (Host): https://www.linkedin.com/in/gigikenneth

💕 Explore More from Asele

Visit: https://www.asele.tech

Try the Asele app: https://asele.health

Join our WhatsApp community: https://chat.whatsapp.com/F8GY4RV7Bm2CtCfq6TONsV

LinkedIn: https://linkedin.com/company/asele

Spotify: https://open.spotify.com/show/6NEsMfkG3dvl0pYXU40Efi